CA2086974A1 - R(+)-terazosin - Google Patents

R(+)-terazosin

Info

Publication number
CA2086974A1
CA2086974A1 CA002086974A CA2086974A CA2086974A1 CA 2086974 A1 CA2086974 A1 CA 2086974A1 CA 002086974 A CA002086974 A CA 002086974A CA 2086974 A CA2086974 A CA 2086974A CA 2086974 A1 CA2086974 A1 CA 2086974A1
Authority
CA
Canada
Prior art keywords
terazosin
hydratet
furanyl
enantiomer
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002086974A
Other languages
French (fr)
Other versions
CA2086974C (en
Inventor
John J. Kyncl
Bruce W. Horrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US07/546,349 priority Critical patent/US5212176A/en
Priority to IE208691A priority patent/IE72967B1/en
Priority to IL9856291A priority patent/IL98562A/en
Priority to DE69118889T priority patent/DE69118889T2/en
Priority to ES91914562T priority patent/ES2089224T3/en
Priority to AT91914562T priority patent/ATE136779T1/en
Priority to PCT/US1991/004562 priority patent/WO1992000073A1/en
Priority to JP3513458A priority patent/JPH07119222B2/en
Priority to AU83231/91A priority patent/AU654148B2/en
Priority to EP91914562A priority patent/EP0536329B1/en
Priority to DK91914562.3T priority patent/DK0536329T3/en
Priority to PT98148A priority patent/PT98148B/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to CA002086974A priority patent/CA2086974C/en
Publication of CA2086974A1 publication Critical patent/CA2086974A1/en
Priority to GR960401733T priority patent/GR3020364T3/en
Application granted granted Critical
Publication of CA2086974C publication Critical patent/CA2086974C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Abstract

R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine hydrochloride or a pharmaceutically acceptable salt or hydratet thereof, substantially free of the S(-)-enantiomer.
CA002086974A 1990-06-29 1993-01-08 R(+)-terazosin Expired - Fee Related CA2086974C (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US07/546,349 US5212176A (en) 1990-06-29 1990-06-29 R(+)-terazosin
IE208691A IE72967B1 (en) 1990-06-29 1991-06-18 R(+)-Terazosin
IL9856291A IL98562A (en) 1990-06-29 1991-06-19 R(+)-2- [4-[(tetrahydro-2-furanyl) carbonyl]-1-piperazinyl] 6-7-dimethoxy-4-quinazolinamine and pharmaceutical compositions containing it
AT91914562T ATE136779T1 (en) 1990-06-29 1991-06-26 R(+)-TERAZOSINE
PCT/US1991/004562 WO1992000073A1 (en) 1990-06-29 1991-06-26 R(+)-terazosin
JP3513458A JPH07119222B2 (en) 1990-06-29 1991-06-26 R (+)-terazosin
AU83231/91A AU654148B2 (en) 1990-06-29 1991-06-26 R(+)-terazosin
EP91914562A EP0536329B1 (en) 1990-06-29 1991-06-26 R(+)-terazosin
DE69118889T DE69118889T2 (en) 1990-06-29 1991-06-26 R (+) - TERAZOSIN
DK91914562.3T DK0536329T3 (en) 1990-06-29 1991-06-26 R (+) - terazosin
ES91914562T ES2089224T3 (en) 1990-06-29 1991-06-26 R (+) - TERAZOSIN.
PT98148A PT98148B (en) 1990-06-29 1991-06-28 PREPARATION PROCESS FOR R (+) - 2- {4 - {(TETRAHYDRO-2-FURANYL) CARBONYL} -1-PYRAZAZYL} -6,7-DIMETHOXY-4-QUINAZOLINAMINE AND THEIR PHARMACEUTICALLY ACCEPTANT, SUBSTANTIALLY, OF ENANTIOMERO S (-) AND OF PHARMACEUTICAL COMPOSITIONS
CA002086974A CA2086974C (en) 1990-06-29 1993-01-08 R(+)-terazosin
GR960401733T GR3020364T3 (en) 1990-06-29 1996-06-27 R(+)-terazosin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/546,349 US5212176A (en) 1990-06-29 1990-06-29 R(+)-terazosin
PCT/US1991/004562 WO1992000073A1 (en) 1990-06-29 1991-06-26 R(+)-terazosin
CA002086974A CA2086974C (en) 1990-06-29 1993-01-08 R(+)-terazosin

Publications (2)

Publication Number Publication Date
CA2086974A1 true CA2086974A1 (en) 1994-07-09
CA2086974C CA2086974C (en) 2001-04-10

Family

ID=25675811

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002086974A Expired - Fee Related CA2086974C (en) 1990-06-29 1993-01-08 R(+)-terazosin

Country Status (14)

Country Link
US (1) US5212176A (en)
EP (1) EP0536329B1 (en)
JP (1) JPH07119222B2 (en)
AT (1) ATE136779T1 (en)
AU (1) AU654148B2 (en)
CA (1) CA2086974C (en)
DE (1) DE69118889T2 (en)
DK (1) DK0536329T3 (en)
ES (1) ES2089224T3 (en)
GR (1) GR3020364T3 (en)
IE (1) IE72967B1 (en)
IL (1) IL98562A (en)
PT (1) PT98148B (en)
WO (1) WO1992000073A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical compositions for treatment of benign prostatic hyperplasia comprising a steroid derivative
NZ257993A (en) * 1992-11-04 1997-05-26 Sepracor Inc Use of (+)-doxazosin and medicament containing the compound
AU5549494A (en) * 1992-11-04 1994-05-24 Sepracor, Inc. Methods and compositions of (+) doxazosin for the treatment of hypertension
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
JPH11507395A (en) * 1995-11-15 1999-06-29 メルク エンド カンパニー インコーポレーテッド Alpha 1a adrenergic receptor antagonist
DE19546573A1 (en) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Crystalline polymorph of terazosin hydrochloride, and process for its preparation
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
US5922722A (en) * 1996-11-12 1999-07-13 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
IT1286789B1 (en) * 1996-11-29 1998-07-17 Alfa Chem Ital PROCESS FOR THE PRODUCTION OF FORM I OF ANHYDROUS MONOCLORIDATE TERAZOSIN
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6037354A (en) 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
AU5234899A (en) 1998-07-30 2000-02-21 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
AU1808400A (en) 1998-10-29 2000-05-22 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
AU1345600A (en) 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
DE19861323B4 (en) * 1998-12-08 2006-02-16 Robert Bosch Gmbh Method for transmitting short messages
DE19856440C2 (en) * 1998-12-08 2002-04-04 Bosch Gmbh Robert Transmission frame and radio unit with transmission frame
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US7335803B2 (en) 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
JP2002121188A (en) * 2000-07-18 2002-04-23 Toray Ind Inc Method for manufacturing piperazine amide compound and piperazine-tetrahydrofuran-2-carboxylic acid amide derivative
US20020198215A1 (en) * 2000-10-23 2002-12-26 Lino Tavares Terazosin transdermal device and methods
US6534542B2 (en) 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
KR20040088519A (en) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. Active Agent Delivery Systems and Methods for Protecting and Administering Active Agents
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
EP2335734A3 (en) 2003-09-12 2012-01-11 Allergan, Inc. Treatment of pain and other alpha 2 adrenergic-mediated conditions
US7390829B2 (en) 2005-06-29 2008-06-24 Allergan, Inc. Alpha-2 adrenergic agonists
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
AU2007286186A1 (en) * 2006-08-08 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
US7598417B2 (en) 2007-04-12 2009-10-06 Allergan, Inc. Substituted fluoroethyl ureas as alpha 2 adrenergic agents
AU2008254717B2 (en) 2007-05-23 2014-06-05 Allergan, Inc. Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
CA2687976C (en) 2007-05-23 2015-04-07 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
US7829587B2 (en) 2008-01-09 2010-11-09 Allergan, Inc. Substituted 2-aminotetralin derivatives as selective alpha 2B agonist
US8809379B2 (en) 2008-01-18 2014-08-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
US8362022B2 (en) 2008-01-18 2013-01-29 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
US20090239918A1 (en) * 2008-03-24 2009-09-24 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
US8420114B2 (en) 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
EP2280707A1 (en) 2008-05-05 2011-02-09 Allergan, Inc. Alpha2b and alpha2c agonists
AU2009246572A1 (en) 2008-05-16 2009-11-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
AU2009333620A1 (en) 2008-12-08 2011-07-07 Allergan, Inc. N-(1-phenyl-2-arylethyl)-4,5-dihydro-3H-pyrrol-2-amine compounds as subtype selective modulators of alpha2B or alpha2B and alpha2C adrenoceptors
US20110306635A1 (en) 2009-02-06 2011-12-15 Allergan ,Inc. Pyridine compounds as subtype selective modulators of alpha2b and /or alpha 2c adrenergic receptors
EP2459542B1 (en) 2009-07-30 2014-10-29 Allergan, Inc. Substituted N-benzyl-4,5-dihydrooxazol-2-amines useful as selective alpha 2B/2C receptor agonists
EP2486009B1 (en) 2009-10-06 2019-08-21 Allergan, Inc. 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11224572B1 (en) * 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
JPH01216983A (en) * 1988-02-26 1989-08-30 Hiroyuki Nohira Method for optical resolution of (+-)-tetrahydrofuran-2-carboxylic acid

Also Published As

Publication number Publication date
ATE136779T1 (en) 1996-05-15
WO1992000073A1 (en) 1992-01-09
AU8323191A (en) 1992-01-23
ES2089224T3 (en) 1996-10-01
EP0536329A1 (en) 1993-04-14
GR3020364T3 (en) 1996-09-30
DK0536329T3 (en) 1996-08-12
DE69118889T2 (en) 1996-11-07
PT98148A (en) 1993-08-31
EP0536329A4 (en) 1993-05-19
CA2086974C (en) 2001-04-10
JPH07119222B2 (en) 1995-12-20
US5212176A (en) 1993-05-18
JPH05507280A (en) 1993-10-21
AU654148B2 (en) 1994-10-27
DE69118889D1 (en) 1996-05-23
PT98148B (en) 1998-12-31
EP0536329B1 (en) 1996-04-17
IL98562A (en) 1995-12-31
IE912086A1 (en) 1992-01-01
IE72967B1 (en) 1997-05-07

Similar Documents

Publication Publication Date Title
CA2086974A1 (en) R(+)-terazosin
LU88842I2 (en) Nebivolol optionally in the form of a pharmaceutically acceptable salt or hydrate, in particular Nebivolol hydrochloride
AU6798790A (en) Teat cup inflation
AU6062590A (en) Pharmaceutically active compounds
CA2163003A1 (en) Solubilizer and external preparations containing the same
USD398466S (en) Toilet tissue roll holder
CA2143263A1 (en) Orally administrable raloxifene formulations
USD340523S (en) Orthodontic bracket base
ZA9110018B (en) 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity.
CA2064373A1 (en) Piperidine derivatives
GR3018031T3 (en) Apparatus for surgically profiling the cornea using vacuum.
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
AU674379B2 (en) Antitussive
USD328845S (en) Retaining ring mounting clamp
USD323043S (en) Ear protector
USD313065S (en) Faucet set
CA2260863A1 (en) Treatment of psychotic disorders
CA2042936A1 (en) Treatment of ocular hypertension with a synergistic combination for ophthalmic use
CA2388830A1 (en) Oral solution containing galanthamine and a sweetening agent
USD320068S (en) Pedestal lavatory
USD332531S (en) Chair
USD324386S (en) Combined earphones and earmuffs
CA2094457A1 (en) Monoquaternary 2,16-bispiperidinylandrostane derivatives
MX9702506A (en) Sabeluzole oral suspensions.
CA2048245A1 (en) Treatment of cataract with prostacyclin compounds

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed